






NANOLOGICA

NLAB SPIRO™


NEXT GENERATION DRUG CARRIER FOR INHALED FORMULATIONS

Nanologica develops nanoporous silica particles as a free-flowing powder tailored for pulmonary drug delivery. Nanologica's NLAB Spiro™ particles solve problems in pharmaceutical formulations by improving solubility, enhancing bioavailability and protecting APIs from degradation.



The spherical particles are produced in the size range of 2 µm to 5 µm, with narrow particle size distribution, optimised to reach the target site in the lung. The particles are non-aggregating, carry a high drug load, offer a controlled release profile and are soluble in simulated lung fluid.

NLAB Spiro™



- Nanoporous spherical particles
- 2 to 5 µm
- Narrow particle size distribution
- Tuneable particle and pore size
- High loading capacity up to 40%
- Free-flowing powder

Business Model


- Licensing agreements/ technology transfer
- Feasibility studies
- Fee for service contracts
- Development of own assets




NLAB SPIRO™

NEXT GENERATION DRUG CARRIER FOR INHALED FORMULATIONS


The aerodynamic properties of the particles are perfectly tailored for inhalation. The MMADs (mass median aerodynamic diameter) shown for the NLAB Spiro™ particles loaded with three different active ingredients give reproducible high delivered dose.



API 1 loaded 25% into NLAB silica. MMAD 1.57µm



API 2 loaded 15 % into NLAB silica, MMAD 1.92µm



API 3 loaded 16 % into NLAB silica, MMAD 3.32µm

- Nanologica has GMP production at ton scale capacity
- Patented process by product and formulation protection.
- NLAB Spiro™ is suitable for most APIs, including smaller biologics
- Enables formulation of several APIs in the same formulation for combination therapy.

Contact

Professor Adam Feiler
Chief Technical Officer
adam.feiler@nanologica.com

Ms. Kia Bengtsson
Director Clinical Development
kia.bengtsson@nanologica.com